Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

South Korea flag South Korea · Delayed Price · Currency is KRW
61,900
+700 (1.14%)
Oct 30, 2025, 3:30 PM KST
1.14%
Market Cap1.87T
Revenue (ttm)7.88B
Net Income (ttm)-23.09B
Shares Out30.22M
EPS (ttm)-770.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume121,653
Average Volume160,867
Open60,300
Previous Close61,200
Day's Range59,400 - 62,400
52-Week Range25,450 - 74,200
Beta0.71
RSI50.32
Earnings DateNov 11, 2025

About Mezzion Pharma

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea. [Read more]

Industry Pharmaceutical Preparations
Founded 2002
Employees 18
Stock Exchange KOSDAQ
Ticker Symbol 140410
Full Company Profile

Financial Performance

In 2024, Mezzion Pharma's revenue was 8.61 billion, a decrease of -72.85% compared to the previous year's 31.72 billion. Losses were -19.48 billion, 53.0% more than in 2023.

Financial Statements

News

There is no news available yet.